How to manage toxicities from Immune Checkpoint Inhibitors?

Speaker: John Haanen

Patients treated with Immune checkpoint inhibitors like anti-CTLA-4, anti-PD-1 and anti-PD-L1 drugs, may develop immune-related adverse events. As any tissue can be involved, it is  very important to recognize these side effects early and manage them promptly and effectively to get the best outcome for the patients.

In this educational video of the 'How To' series, John Haanen explains how to manage immunotherapy induced colitis, hepatitis and pneumonitis.

 

References:

J B A G Haanen, F Carbonnel, C Robert, K M Kerr, S Peters, J Larkin, K Jordan, on behalf of the ESMO Guidelines Committee; Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up , Annals of Oncology, Volume 28, Issue suppl_4, 1 July 2017, Pages iv119–iv142, https://doi.org/10.1093/annonc/mdx225

View and download the ESMO Guidelines Slide Set on Management of toxicities from immunotherapy